Organogenesis Holdings Valuation
| ORGO Stock | USD 3.73 0.03 0.80% |
At this time, the company appears to be undervalued. Organogenesis Holdings holds a recent Real Value of $4.9 per share. The prevailing price of the company is $3.73. Our model determines the value of Organogenesis Holdings from analyzing the company fundamentals such as Return On Equity of 0.003, operating margin of 0.15 %, and Shares Outstanding of 126.91 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Organogenesis Holdings' valuation include:
Price Book 1.8754 | Enterprise Value | Enterprise Value Ebitda 198.1589 | Price Sales 1.0257 | Forward PE 12.3153 |
Undervalued
Today
Please note that Organogenesis Holdings' price fluctuation is moderately volatile at this time. Calculation of the real value of Organogenesis Holdings is based on 3 months time horizon. Increasing Organogenesis Holdings' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Organogenesis Holdings is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Organogenesis Stock. However, Organogenesis Holdings' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.73 | Real 4.9 | Target 8.5 | Hype 3.37 |
The intrinsic value of Organogenesis Holdings' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Organogenesis Holdings' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Organogenesis Holdings helps investors to forecast how Organogenesis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Organogenesis Holdings more accurately as focusing exclusively on Organogenesis Holdings' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Organogenesis Holdings' intrinsic value based on its ongoing forecasts of Organogenesis Holdings' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Organogenesis Holdings' closest peers.
Organogenesis Holdings Cash |
|
Organogenesis Revenue by Product
Organogenesis Holdings Total Value Analysis
Organogenesis Holdings is now forecasted to have valuation of 586.37 M with market capitalization of 477.19 M, debt of 43.31 M, and cash on hands of 113.24 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Organogenesis Holdings fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
586.37 M | 477.19 M | 43.31 M | 113.24 M |
Organogenesis Holdings Investor Information
About 47.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.88. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Organogenesis Holdings recorded a loss per share of 0.08. The entity had not issued any dividends in recent years. Based on the key indicators related to Organogenesis Holdings' liquidity, profitability, solvency, and operating efficiency, Organogenesis Holdings may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Organogenesis Holdings Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Organogenesis suggests not a very effective usage of assets in February.Organogenesis Holdings Profitability Analysis
Based on Organogenesis Holdings' profitability indicators, Organogenesis Holdings' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Organogenesis Holdings' ability to earn profits and add value for shareholders.Net Income | First Reported 2016-03-31 | Previous Quarter -9.4 M | Current Value 21.6 M | Quarterly Volatility 13 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.58 | 0.68 |
|
|
For Organogenesis Holdings profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Organogenesis Holdings to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Organogenesis Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Organogenesis Holdings's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Organogenesis Holdings over time as well as its relative position and ranking within its peers.
Organogenesis Holdings Earnings per Share Projection vs Actual
The next projected EPS of Organogenesis Holdings is estimated to be 0.0425 with future projections ranging from a low of 0.0425 to a high of 0.0425. Organogenesis Holdings' most recent 12-month trailing earnings per share (EPS TTM) is at -0.08. Please be aware that the consensus of earnings estimates for Organogenesis Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.Organogenesis Holdings Earnings Estimation Breakdown
The calculation of Organogenesis Holdings' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Organogenesis Holdings is estimated to be 0.0425 with the future projection ranging from a low of 0.0425 to a high of 0.0425. Please be aware that this consensus of annual earnings estimates for Organogenesis Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.04 Lowest | Expected EPS | 0.04 Highest |
Organogenesis Holdings Earnings Projection Consensus
Suppose the current estimates of Organogenesis Holdings' value are higher than the current market price of the Organogenesis Holdings stock. In this case, investors may conclude that Organogenesis Holdings is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Organogenesis Holdings' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 2 | 29.96% | 0.0 | 0.0425 | -0.08 |
Organogenesis Holdings Ownership Allocation
Organogenesis Holdings owns a total of 126.91 Million outstanding shares. Over half of Organogenesis Holdings' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Also note that almost two million six hundred sixty-five thousand one hundred fifty-five invesors are currently shorting Organogenesis Holdings expressing very little confidence in its future performance.Organogenesis Holdings Profitability Analysis
The company reported the previous year's revenue of 482.04 M. Net Income was 861 K with profit before overhead, payroll, taxes, and interest of 346.56 M.About Organogenesis Holdings Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Organogenesis Holdings. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Organogenesis Holdings based exclusively on its fundamental and basic technical indicators. By analyzing Organogenesis Holdings's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Organogenesis Holdings's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Organogenesis Holdings. We calculate exposure to Organogenesis Holdings's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Organogenesis Holdings's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 421.2 M | 442.3 M | |
| Pretax Profit Margin | (0.01) | (0.01) | |
| Gross Profit Margin | 0.68 | 0.58 |
Organogenesis Holdings Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 131.7 M | |
| Quarterly Earnings Growth Y O Y | 0.222 | |
| Forward Price Earnings | 12.3153 |
Organogenesis Holdings Current Valuation Indicators
Organogenesis Holdings' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Organogenesis Holdings' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Organogenesis Holdings, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Organogenesis Holdings' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Organogenesis Holdings' worth.When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could Organogenesis diversify its offerings? Factors like these will boost the valuation of Organogenesis Holdings. Anticipated expansion of Organogenesis directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organogenesis Holdings data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.222 | Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.31 | Return On Assets |
Investors evaluate Organogenesis Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organogenesis Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organogenesis Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between Organogenesis Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organogenesis Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organogenesis Holdings' market price signifies the transaction level at which participants voluntarily complete trades.